

**CORRECTION**

Correction: Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer

Taichi Kuwahara¹, Shoichi Hazama^{1,2}, Nobuaki Suzuki¹, Shin Yoshida¹, Shinobu Tomochika¹, Yuki Nakagami^{1,2}, Hiroto Matsui¹, Yoshitaro Shindo¹, Shinsuke Kanekiyo¹, Yukio Tokumitsu^{1,2}, Michihisa Iida¹, Ryouichi Tsunedomi¹, Shigeru Takeda¹, Shigefumi Yoshino³, Naoko Okayama⁴, Yutaka Suehiro⁵, Takahiro Yamasaki⁵, Tomonobu Fujita⁶, Yutaka Kawakami⁶, Tomio Ueno⁷ and Hiroaki Nagano¹

British Journal of Cancer (2019) 121:983–984; <https://doi.org/10.1038/s41416-019-0605-4>

Correction to: *British Journal of Cancer* (2019) **121**, 659–665; <https://doi.org/10.1038/s41416-019-0559-6>; published online 6 September 2019.

The original version of this article contained an error in Figs. 3i, j. The key for each should read CD4 High + FOXP3 High, CD4 High + FOXP3 Low, CD4 Low + FOXP3 High, CD4 Low + FOXP3 Low. The corrected figure is below. The interpretation of the data and conclusions are not affected.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019

¹Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan; ²Department of Translational Research and Developmental Therapeutics against Cancer, Yamaguchi University Faculty of Medicine, Ube, Yamaguchi 755-8505, Japan; ³Oncology Center, Yamaguchi University Hospital, Ube, Yamaguchi 755-8505, Japan; ⁴Division of Laboratory, Yamaguchi University Hospital, Ube, Yamaguchi 755-8505, Japan; ⁵Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan; ⁶Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Shinjuku, Tokyo 160-8582, Japan and ⁷Department of Digestive Surgery, Kawasaki Medical University, Kurashiki 701-0192 Okayama, Japan

Correspondence: Hiroaki Nagano (hnagano@yamaguchi-u.ac.jp)

Published online: 17 October 2019




Fig. 3